Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma [0.03%]
紧密连接蛋白作为治疗肝纤维化和肝细胞癌的治疗靶点
Antonio Saviano,Natascha Roehlen,Thomas F Baumert
Antonio Saviano
In the last decade tight junction proteins exposed at the surface of liver or cancer cells have been uncovered as mediators of liver disease biology: Claudin-1 and Occludin are host factors for hepatitis C virus entry and Claudin-1 has been...
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease? [0.03%]
一般人群和肝病患者的安全饮酒量限度是多少？
Manuel Romero-Gómez,Juan Pablo Arab,Claudia P Oliveira et al.
Manuel Romero-Gómez et al.
Excessive alcohol consumption represents an important burden for health systems worldwide and is a major cause of liver- and cancer-related deaths. Alcohol consumption is mostly assessed by self-report that often underestimates the amount o...
Naoto Fujiwara,Genki Kimura,Hayato Nakagawa
Naoto Fujiwara
Spatial transcriptomics, leveraging sequencing- and imaging-based techniques, has emerged as a groundbreaking technology for mapping gene expression within the complex architectures of tissues. This approach provides an in-depth understandi...
New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice [0.03%]
非酒精性脂肪肝病的新命名：代谢异常相关脂肪性肝病的临床实践含义及与代谢异常和饮酒相关的肝脏疾病的影响
Clémence M Canivet,Jérôme Boursier,Rohit Loomba
Clémence M Canivet
In June 2023, under the patronage of the American Association for Study of Liver Disease, the European Association for Study of the Liver, and the Asociación Latinoamericana para el Estudio del Hígado with the involvement of 236 participa...
Takahiro Kodama,Tetsuo Takehara
Takahiro Kodama
This review examines the latest epidemiological and molecular pathogenic findings of metabolic-associated hepatocellular carcinoma (HCC). Its increasing prevalence is a significant concern and reflects the growing burden of obesity and meta...
Marialena Mouzaki,Jessica G Woo,Senad Divanovic
Marialena Mouzaki
Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is common and can be seen as early as in utero. A growing body of literature suggests that gestational and early life exposures modify the risk of MASLD development ...
Anna Tutusaus,Albert Morales,Pablo García de Frutos et al.
Anna Tutusaus et al.
TAM (TYRO3, AXL, and MERTK) protein tyrosine kinase membrane receptors and their vitamin K-dependent ligands GAS6 and protein S (PROS) are well-known players in tumor biology and autoimmune diseases. In contrast, TAM regulation of fibrogene...
UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis [0.03%]
UDCA对药物性肝病的临床和病理生理学依据
Fernando Bessone,Geraldine L Hillotte,Natalia Ahumada et al.
Fernando Bessone et al.
Drug-induced liver injury (DILI) is an adverse reaction to medications and other xenobiotics that leads to liver dysfunction. Based on differential clinical patterns of injury, DILI is classified into hepatocellular, cholestatic, and mixed ...
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease [0.03%]
与代谢功能障碍相关性脂肪肝疾病的个体化治疗模型
Mohamed El-Kassas,Abeer Awad,Mohamed Elbadry et al.
Mohamed El-Kassas et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, an...
Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting [0.03%]
初级保健环境中早期检测隐性肝纤维化的算法
Katrine Tholstrup Bech,Katrine Prier Lindvig,Maja Thiele et al.
Katrine Tholstrup Bech et al.
More than one-third of the adult world population has steatotic liver disease (SLD), with a few percent of individuals developing cirrhosis after decades of silent liver fibrosis accumulation. Lack of systematic early detection causes most ...